Who makes Aliskiren 150 mg?

Aliskiren 150 mg is developed by Novartis Pharmaceuticals.

What development phase is Aliskiren 150 mg in?

Aliskiren 150 mg is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Aliskiren 150 mg

Novartis Pharmaceuticals · FDA-approved active Small molecule Quality 5/100

At a glance

Generic name	Aliskiren 150 mg
Also known as	Tekturna
Sponsor	Novartis Pharmaceuticals
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy (PHASE2)
Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension (PHASE1)
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension (PHASE4)
Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension (PHASE4)
Aldosterone and the Metabolic Syndrome (PHASE1)
Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation (PHASE4)
Vitamin D Deficiency in Patients With Hypertension (PHASE4)
Shiga Microalbuminuria Reduction Trial-2 (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Aliskiren 150 mg CI brief — competitive landscape report
Aliskiren 150 mg updates RSS · CI watch RSS
Novartis Pharmaceuticals portfolio CI